Defunct Company
Total Trials
2
As Lead Sponsor
As Collaborator
0
Total Enrollment
1,213
NCT02600611
Phase 3 Study to Evaluate Safety and Efficacy of Iclaprim Versus Vancomycin for ABSSSI: REVIVE-1
Phase: Phase 3
Role: Lead Sponsor
Start: Nov 1, 2015
Completion: Jan 30, 2017
NCT02607618
Phase 3 Study to Evaluate Safety and Efficacy of Iclaprim Versus Vancomycin for ABSSSI: REVIVE-2
Start: Nov 30, 2015
Completion: Aug 8, 2017